A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors.

Trial Profile

A Phase 1 Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2012

At a glance

  • Drugs Erlotinib; Tivantinib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Sep 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Additional lead investigators (Just RG, Rosen L) as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top